Kiromic Biopharma Stock Current Valuation
Valuation analysis of Kiromic Biopharma helps investors to measure Kiromic Biopharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Kiromic Biopharma Company Current Valuation Analysis
Kiromic Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Kiromic Biopharma Current Valuation | 9.55 M |
Most of Kiromic Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kiromic Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Kiromic Biopharma has a Current Valuation of 9.55 M. This is 99.93% lower than that of the Biotechnology sector and 99.79% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.94% higher than that of the company.
Kiromic Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kiromic Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kiromic Biopharma could also be used in its relative valuation, which is a method of valuing Kiromic Biopharma by comparing valuation metrics of similar companies.Kiromic Biopharma is currently under evaluation in current valuation category among its peers.
Kiromic Fundamentals
| Return On Equity | -11.3 | ||||
| Return On Asset | -0.92 | ||||
| Current Valuation | 9.55 M | ||||
| Shares Outstanding | 1.18 M | ||||
| Shares Owned By Insiders | 3.91 % | ||||
| Shares Owned By Institutions | 68.00 % | ||||
| Number Of Shares Shorted | 45.74 K | ||||
| Price To Book | 15.11 X | ||||
| EBITDA | (29.44 M) | ||||
| Net Income | (34.73 M) | ||||
| Cash And Equivalents | 6.51 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 9.41 M | ||||
| Debt To Equity | 0.20 % | ||||
| Current Ratio | 1.35 X | ||||
| Book Value Per Share | (5.35) X | ||||
| Cash Flow From Operations | (23.75 M) | ||||
| Short Ratio | 0.93 X | ||||
| Earnings Per Share | (39.68) X | ||||
| Number Of Employees | 31 | ||||
| Beta | 0.16 | ||||
| Market Capitalization | 2.15 M | ||||
| Total Asset | 11.97 M | ||||
| Retained Earnings | (101.95 M) | ||||
| Working Capital | (11.59 M) | ||||
| Z Score | -21.07 | ||||
| Net Asset | 11.97 M |
Pair Trading with Kiromic Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kiromic Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kiromic Biopharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to TechnipFMC PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TechnipFMC PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TechnipFMC PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TechnipFMC PLC to buy it.
The correlation of TechnipFMC PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TechnipFMC PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TechnipFMC PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TechnipFMC PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Kiromic Stock
If you are still planning to invest in Kiromic Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kiromic Biopharma's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |